Evaluation of the BRCA1/2 mutation as a prognostic marker in primary peritoneal serous cancer


Introduction: The present study was a retrospective investigation of the relation between immunohistochemical BRCA1/2 status and prognosis in patients with primary peritoneal serous cancer (PPSC). Materials and Methods: We retrospectively evaluated 14 consecutive patients diagnosed with PPSC other than hereditary breast and ovarian cancer between 2005 and 2010. All patients had serum CA125 levels >40 U/mL prior to starting first-line chemotherapy with paclitaxel and carboplatin. Paclitaxel was administered as a 3-hour intravenous infusion at a dose of 175 mg/m2 on day 1, and carboplatin was delivered at an area under the curve of 5 based on the Calvert method. Patients received six cycles of first-line chemotherapy, except patients whose disease was determined to be progressive during the chemotherapy regimen. BRCA1/2 and p53 protein expression was determined by immunohistochemistry of patient tissue samples. The Cox proportional hazards model was used to evaluate univariate and independent multivariate associations with the effect of clinical parameters, such as age at diagnosis; tumor histology; tumor grade; and rate of change in CA125, and BRCA1/2, p53 status on overall survival. Probability values of less than 0.05 were considered to indicate statistical significance. Results: Two cases (14%) had the BRCA1 mutation, and none had the BRCA2 mutation. Eleven cases (79%) were positive for p53. In the univariate analysis, factors significantly associated with overall survival were (pre-chemotherapy CA125-pre-2nd chemotherapy CA125)/pre-chemotherapy CA125 (p = 0.0034) and (pre-chemotherapy CA125-pre-3rd chemotherapy CA125)/pre-chemotherapy CA125 (p = 0.0245). BRCA1 and p53 status were not predictors of overall survival. Multivariate analysis performed with overall survival as an endpoint revealed that none of the factors examined was significant. Median survival rate of patients without a BRCA1 mutation was 23.5 months (2 - 82 months), and all died. By contrast, one patient with a BRCA1 mutation remains alive at 85 months, and the other patient died at 64 months. Conclusion: BRCA1 might be a predictor of overall survival in patients with PPSC receiving chemotherapy.

Share and Cite:

Furukawa, N. , Ohno, S. , Kasai, T. , Morioka, S. , Ito, F. , Tanase, Y. , Haruta, S. , Kanayama, S. , Kawaguchi, R. , Yoshida, S. and Kobayashi, H. (2013) Evaluation of the BRCA1/2 mutation as a prognostic marker in primary peritoneal serous cancer. Open Journal of Obstetrics and Gynecology, 3, 653-657. doi: 10.4236/ojog.2013.39119.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Ushijima, K. (2009) Current status of gynecologic cancer in Japan. Journal of Gynecologic Oncology, 20, 67-71. http://dx.doi.org/10.3802/jgo.2009.20.2.67
[2] Matsuda, T., Marugame, T., Kamo, K., et al. (2012) Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Japanese Journal of Clinical Oncology, 42, 139-147.
[3] Metser, U., Jones, C., Jacks, L.M., Bernardini M.Q. and Ferguson, S. (2011) Identification and quantification of peritoneal metastases in patients with ovarian cancer with multidetector computed tomography: Correlation with surgery and surgical outcome. International Journal of Gynecological Cancer, 21, 1391-1398. http://dx.doi.org/10.1097/IGC.0b013e31822925c0
[4] Vasey, P.A., Jayson, G.C., Gordon, A., et al. (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute, 96, 1682-1691. http://dx.doi.org/10.1093/jnci/djh323
[5] du Bois, A., Luck, H.J., Meier, W., et al. (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute, 95, 1320-1329. http://dx.doi.org/10.1093/jnci/djg036
[6] Shih Ie, M. and Kurman, R.J. (2004) Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. American Journal of Pathology, 164, 1511-1518.
[7] Koul, A., Malander, S., Loman, N., et al. (2000) BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features. International Journal of Gynecological Cancer, 10, 289-295. http://dx.doi.org/10.1046/j.1525-1438.2000.010004289.x
[8] Hennessy, B.T., Timms, K.M., Carey, M.S., et al. (2010) Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. Journal of Clinical Oncology, 28, 3570-3576. http://dx.doi.org/10.1200/JCO.2009.27.2997
[9] Quinn, J.E., James, C.R., Stewart, G.E., et al. (2007) BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clinical Cancer Research, 13, 7413-7420.
[10] Alsop, K., Fereday, S., Meldrum, C., et al. (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 30, 2654-2663. http://dx.doi.org/10. 1200/JCO.2011.39.8545
[11] Schorge, J.O., Muto, M.G., Lee, S.J., et al. (2000) BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Research, 60, 1361-1364.
[12] Skytte, A.B., Waldstrom, M., Rasmussen, A.A., Cruger, D., Woodward, E.R., Kolvraa, S. (2011) Identification of BRCA1-deficient ovarian cancers. Acta Obstetricia et Gynecologica Scandinavica, 90, 593-599. http://dx.doi.org/10.1111/j.1600-0412.2011.01121.x
[13] Chu, C.S., Menzin, A.W., Leonard, D.G., Rubin, S.C. and Wheeler, J.E. (1999) Primary peritoneal carcinoma: A review of the literature. Obstetrical & Gynecological Survey, 54, 323-335.
[14] Eltabbakh, G.H., Piver, M.S., Natarajan, N. and Mettlin, C.J. (1998) Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstetrical & Gynecological, 91, 254-259. http://dx.doi.org/10.1016/S0029-7844(97)00650-9
[15] Folkins, A.K., Jarboe, E.A., Roh, M.H. and Crum, C.P. (2009) Precursors to pelvic serous carcinoma and their clinical implications. Gynecologic Oncology, 113, 391-396. http://dx.doi.org/10.1016/j.ygyno. 2009.01.013
[16] Ramos, J., Gunturu, K.S., Krishnamoorthy, S., Kenney, B. and Saif, M.W. (2011) Primary peritoneal carcinoma in complete remission: A case report. Anticancer Research, 31, 4397-4400.
[17] Pal, T., Permuth-Wey, J., Kapoor, R., Cantor, A. and Sutphen R. (2007) Improved survival in BRCA2 carriers with ovarian cancer. Familial Cancer, 6, 113-119. http://dx.doi.org/10.1007/s10689-006-9112-x
[18] Hyman, D.M., Zhou, Q., Iasonos, A., et al. (2012) Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer, 118, 3703-3709. http://dx.doi.org/10.1002/cncr.26655
[19] Lee, Y., Miron, A., Drapkin, R., et al. (2007) A candidate precursor to serous carcinoma that originates in the distal fallopian tube. The Journal of Pathology, 211, 26-35. http://dx.doi.org/10.1002/ path.2091
[20] Shaw, P.A., Rouzbahman, M., Pizer, E.S., Pintilie, M. and Begley, H. (2009) Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Modern Pathology, 22, 1133-1138. http://dx.doi.org/10.1038/modpathol.2009.89
[21] Folkins, A.K., Jarboe, E.A., Saleemuddin, A., et al. (2008) A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecologic Oncology, 109, 168-173. http://dx.doi.org/10.1016/j.ygyno.2008.01.012
[22] Mehra, K.K., Chang, M.C., Folkins, A.K., et al. (2011) The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls. Modern Pathology, 24, 152-156. http://dx.doi.org/10.1038/modpathol.2010.171
[23] Vasudev, N.S., Trigonis, I., Cairns, D.A., et al. (2011) The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Archives of Gynecology and Obstetrics, 284, 221-227. http://dx.doi.org/10.1007/s00404-010-1655-2
[24] Furukawa, N., Sasaki, Y., Shigemitsu, A., et al. (2013) CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer. Journal of Gynecologic Oncology, 24, 141-145. http://dx.doi.org/10.3802/jgo. 2013.24.2.141

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.